About the B2B Uro-Oncology: GU Cancers Triad  

The rapidly evolving treatment landscape for bladder, kidney, and prostate cancers poses a challenge for urologists, medical oncologists, and radiation oncologists alike. In managing these GU cancers, physicians need to keep up with new data on therapeutic options, provide individualized care through a multidisciplinary approach, and use optimal treatment sequence or combinations while effectively managing side effects. 

Aiming to support the educational needs of urologists and allied healthcare practitioners, the B2B Uro-Oncology: GU Cancers Triad meeting will feature multidisciplinary, scientific, and educational sessions highlighting cutting-edge content in management of the most prevalent GU malignancies: prostate, bladder, and kidney cancers. Through state-of-the-art presentations, timely debates, and interactive panel discussions, world-renowned experts in GU oncology will: 

• Examine advances in biomarkers to guide the diagnosis and treatment of GU cancers
• Discuss recent developments in local and systemic therapy approaches in GU oncology and their implications for clinical practice 
• Evaluate new diagnostic and surgical technologies changing the landscape of GU cancers management 
• Summarize emerging data of key ongoing clinical trials in the uro-oncology space 
• Provide an overview of the five practice changes shaping the GU cancers practice in coming years